A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps
Key facts
- Who runs it
- Sanofi
- Where
- Atlanta, Bellaire, Boise, Boston, Dallas, La Jolla, McKinney, Norfolk, Ogden, Roseville, San Antonio, San Diego, Tampa, and Tulsa, United StatesSee the 14 sitesAlso in 5 other countries, 15 sites
- Trial code
- NCT06454240
- EudraCT 2024-511261-11
- U1111-1300-6978
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 79 people enrolled
- Started
- 17 Jul 2024
- Ended
- 23 Apr 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- lunsekimig
- placebo
- Record updated
- 28 April 2026
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- A minimum bilateral nasal polyp score of 5 out of a maximum score of 8 for both nostrils (with at least a score of 2 for each nostril) despite use of intranasal corticosteroid treatment for at least 2 months prior to screening; Ongoing symptoms for at least 2 months prior to screening, including:
- Nasal congestion, blockage, or obstruction with moderate or severe symptom severity at screening (Score 2 or 3 on NC Score) and a weekly average severity score of at least 1 (range 0 to 3) at randomization (NC Score: 0=no symptoms, 1=mild, 2=moderate, and 3=severe)
- At least 1 of the following 2 symptoms: (1) partial loss of smell (hyposmia) or total loss of smell (anosmia); (2) anterior and/or posterior rhinorrhea
Who cannot take part
- Patient who has received any therapies such as for example systemic corticosteroids, anti-IgE therapy, monoclonal antibody and some others in the specified timeframe(s) prior to the screening visit
- Patients who have undergone any nasal/sinus surgery within 6 months before screening or for whom NPS cannot be determined accurately on endoscopy due to anatomic changes to the nasal cavity from past nasal/sinus surgery
- Patients with conditions/concomitant diseases making them non evaluable for the primary efficacy endpoint
- Signs or a CT scan suggestive of Allergic fungal rhinosinusitis
- Active/chronic helminthic infection
- History of human immunodeficiency virus (HIV) infection or positive HIV screen (Anti-HIV- and HIV-2 antibodies) at screening visit
- Patients with positive or indeterminate hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis C antibody at screening visit NOTE: The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
- Participants are excluded from the study if any of the following criteria apply:
Where in United States
Also in 5 other countries, 15 sites
- Emory University Hospital Midtown- Site Number : 8400012Atlanta, United States
- McGovern Medical School - UT Physicians Dermatology - Bellaire Station- Site Number : 8400017Bellaire, United States
- The Allergy Group - Asthma & Allergy Boise- Site Number : 8400002Boise, United States
- Harvard Medical School - Brigham and Women's Hospital Site Number : 8400016Boston, United States
- Gary Gross Pharmaceutical Research & Consulting, Inc. Site Number : 8400004Dallas, United States
- La Jolla, CaliforniaHospital not named in the registry
- Berkson Medical - McKinney- Site Number : 8400014McKinney, United States
- Eastern Virginia Medical School (EVMS) Medical Group- Site Number : 8400008Norfolk, United States
- Advanced Research Institute - Odgen- Site Number : 8400022Ogden, United States
- Sacramento Ear Nose & Throat - Roseville- Site Number : 8400003Roseville, United States
- San Antonio, TexasHospital not named in the registry
- Senta Clinic- Site Number : 8400025San Diego, United States
- James A Haley Veterans' Hospital- Site Number : 8400015Tampa, United States
- Essential Medical Research- Site Number : 8400020Tulsa, United States
About the trial
What the trial wants to find out
This is a parallel, Phase 2, 2-arm, multicenter, randomized, double-blind, placebo-controlled, proof-of-concept study for treatment of CRSwNP.
Read full original descriptionShow less
The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with subcutaneous lunsekimig in adult participants (aged 18 to 70 years, inclusive) with CRSwNP who are inadequately controlled on intranasal corticosteroid treatment. Participants with and without co-morbid asthma will be included in the study, and lung function will be assessed in both groups.
The study duration will be up to approximately 40 weeks per participant, including 4 weeks of screening run-in period, 24 weeks of intervention period, and 12 weeks of follow-up.
The 2 groups in the trial
- Arm 1Placebo, for comparison
Participant will receive placebo subcutaneous (SC) every 4 weeks and intranasal mometasone furoate nasal spray (MFNS) for 24 weeks.
Treatment: placebo
- Arm 2Treatment being tested
Participant will receive lunsekimig subcutaneous (SC) every 4 weeks and intranasal mometasone furoate nasal spray (MFNS) for 24 weeks.
Treatment: lunsekimig
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- Record updated
- 28 April 2026